ONCN Stock Chart & Stats
$2530.00
$0.00(0.00%)
At close: 4:00 PM EDT
$2530.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,530.00 - $2,530.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$719.32B
Enterprise Value$29.79K
Total Cash (Recent Filing)$5.10B
Total Debt (Recent Filing)$1.14B
Price to Earnings (P/E)25.7
Beta0.00
Next Earnings
Nov 05, 2026EPS Estimate
33.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)76.57
Shares Outstanding109,786,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)7.60
Price to Sales (P/S)6.20
P/FCF Ratio35.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7,431.50Price Target Upside193.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)126.19
Revenue Forecast (FY)$116.96B
Bulls Say, Bears Say
Bulls Say
BRUKINSA Market LeadershipBRUKINSA’s leadership position, rapid revenue growth, broad geographic reach, and treatment of more than 300,000 patients provide a substantial commercial foundation. This scale can support durable cash generation, reinforce physician adoption, and fund continued expansion into additional indications.
Strong Profitability And Cash GenerationRecent operating performance shows that BeOne is converting its commercial growth into meaningful cash, not merely accounting earnings. Strong free cash flow improves financial flexibility, supports pipeline investment and manufacturing expansion, and provides resilience while the company scales globally.
Broad Pipeline And Regulatory ProgressMultiple regulatory and late-stage development milestones broaden BeOne’s future growth opportunities beyond its current commercial base. A wider portfolio can diversify product concentration, extend oncology capabilities, and create additional drivers of revenue and market access over the next several years.
Bears Say
Intensifying Competitive PressureCompetition could pressure BeOne’s future growth if alternative BTK and combination regimens gain physician adoption or receive stronger clinical positioning. Even without a meaningful U.S. impact yet, aggressive peer activity may increase commercial spending and make market-share expansion harder.
Uncertainty In CELESTIAL-301The missed uMRD superiority bar creates uncertainty around the regimen’s differentiation and potential regulatory or clinical reception. Although the trial continues to the primary PFS endpoint, an inconclusive interim signal could limit confidence in one avenue of pipeline expansion.
Higher Operating Investment And Earnings VolatilityHigher operating expenses are intended to fund commercial and pipeline investment, but they can constrain margin expansion if growth or launches underperform. The history of negative cash flow through 2024 also shows that recent strong conversion has not yet been demonstrated across a full business cycle.
BeOne Medicines News
ONCN FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $2530.00 and its highest was $2530.00 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $719.32B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Nov 05, 2026 which is in 39 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Aug 05, 2026. The company reported $36.242 earnings per share for the quarter, beating the consensus estimate of $29.365 by $6.877.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 33.61.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,786,920 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $36.242 in its last earnings report, beating expectations of $29.365. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in MX:ONCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7,431.50 (193.74% Upside)
$7,431.50 (193.74% Upside)
Blogger Sentiment
Bullish
MX:ONCN Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $13.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BeOne Medicines
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
ONCN Company Deck
ONCN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive commercial and financial picture: robust revenue and EPS growth, raised full‑year guidance, doubled free cash flow, high gross margins, and multiple meaningful regulatory and late‑stage pipeline milestones (MANGROVE result, BEQALZI approval, BTK degrader progress). Headwinds and uncertainties were present but limited relative to the strength described — including a missed uMRD superiority in CELESTIAL‑301 (though PFS remains the primary endpoint), a $60 million tax settlement, increased operating expense guidance to fund pipeline investment, and ongoing competitive dynamics. On balance, the company emphasized durable demand for BRUKINSA, expanding global footprint, and an accelerating late‑stage pipeline, leading to an overall favorable outlook.View all MX:ONCN earnings summariesONCN Stock 12 Month Forecast
Average Price Target
$7,431.50
▲(193.74% Upside)